echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 76 listed companies have been investigated by institutions, and the head of medical devices has been "stepped on the threshold"

    76 listed companies have been investigated by institutions, and the head of medical devices has been "stepped on the threshold"

    • Last Update: 2022-10-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to the data of Oriental Wealth Network, this week (October 24-October 28), institutions surveyed a total of 76 listed companies, of which Zhongke Chuangda has attracted special attention from institutions, and this week's research activities have attracted a total of 304 institutional surveys
    .
    From the perspective of the industries of the companies intensively researched by the institution, they are mainly concentrated in electronics, medicine and biology and other industries
    .

     
    76 listed companies have been investigated by institutions, and the head of medical devices has been "stepped on the threshold" (Image source: Pharma.
    com)
     
    This week (October 24-October 28), the pharmaceutical and biological industry is still favored by institutions, and the institutions have investigated a large number of companies including Yuyue Medical, Salubris, Puli Pharmaceutical, Chutian Technology, Kaikai Medical, RheinBiologics, Dirui Medical, etc.
    , and the number of research institutions is basically more than 20.


     
    Among them, 4 medical device companies have been "stepping on the threshold" and have received the attention of more than 100 institutions, namely opening medical (277 institutions), Haier Biotechnology (234 institutions), Yuyue Medical (143 institutions), and Chutian Technology (124 institutions).


     
    On October 25, 2022, Medical Device Company opened medical treatment and received hundreds of institutions such as Founder Securities Research Institute, Green Court Capital Management Ltd, and China Europe Fund, and the main content of the research activities revolved around the company's business situation in the first three quarters and the expectations
    for the fourth quarter 。 Open Medical said that in the first three quarters of 2022, the company's ultrasound revenue is about 800 million, a year-on-year increase of more than 20%, soft mirror revenue is about 3.
    3-340 million, a year-on-year increase of more than 60%, hard mirror revenue is close to 40 million, a year-on-year increase of about 300%, and endoscopic therapeutic device business revenue is about 44 million, a year-on-year decrease of about 17%.

    The company's revenue guidance for the full year 2022 remains unchanged, and hopes to achieve steady growth in the ultrasound business (about 15%) and a high growth rate in the endoscopy business (40-50%)
    .

     
    Haier Biologics, which started with cryogenic storage equipment, replied
    to eight questions in the Q&A session, including the development of business in the domestic market, overseas market layout, and future development strategy.
    At present, the total number of the company's overseas network has exceeded 700,
    covering a total of more than 130 countries.
    In recent years, the company has also accelerated the localization construction, and has established local sales teams in Europe, America, Southeast Asia and other places to grasp user needs in a timely manner; Establish experience and training centers in Asia, Africa and other regions, and establish local storage centers in Europe, America and other places to shorten the product delivery cycle
    .
    In the future, the company will continue to expand around the two major fields of life science and medical innovation, and accelerate the layout of new industries through the "endogenous + extension" method
    .

     
    Yuyue Medical, which is also a medical device company, was also asked about its overseas business, saying that with the deepening of the localization strategy, the company's overseas sales are expected to continue to grow
    .
    The company will also pay attention to suitable targets and accelerate the expansion of overseas market scale
    through mergers and acquisitions.
    In recent years, the company's overseas business mainly focuses on Southeast Asia, South America, Africa and other regions, and this year has gradually solved problems such as product access in specific regions.


     
    In addition, Chutian Technology, a leading enterprise of domestic pharmaceutical equipment, has also attracted the attention of more than 100 institutions, including 20 fund management companies, 20 securities companies, 15 investment companies, and 14 asset management companies
    .
    Chutian Technology is mainly engaged in the development, production and sales of pharmaceutical packaging machinery, food packaging machinery and
    other general machinery series products.
    The company said in the institutional question session that the company has always paid attention to the creation and improvement
    of innovation ability, delivery ability, quality assurance ability, market development ability and operation ability.
    The third quarterly report of 2022 shows that the company's main revenue is 4.
    495 billion yuan, a year-on-year increase of 22.
    06%; The net profit attributable to the parent was 463 million yuan, a year-on-year increase of 15.
    32%.


     
    Institutional research has long been regarded by investors as an investment "weather vane"
    .
    Medical devices are a knowledge-intensive industry closely related to human life and health, with a huge market scale, and under the trend of new medical infrastructure, with the promotion of multi-party favorable policies, the future development potential is full
    .
    The industry expects that from 2022 to 2025, the medical device industry will continue to be prosperous
    .

     
    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    appendChild(createElement('script')).
    src='http://bdimg.
    share.
    baidu.
    com/static/api/js/share.
    js?v=89860593.
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.